IR vs SYRE · P/E 49, rev $7.65B vs $7.60B cap
Ingersoll Rand Inc (IR) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported IR revenue for 2025-12-31 was $7.65B. Net income was $581.4M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
IR currently screens at market cap $28.27B and trailing P/E 48.8. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the IR and SYRE stock pages for the full models.
Not investment advice.